Institute of Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, Texas 76107 USA ; Department of Psychiatry and Behavioral Health, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, Texas 76107 USA.
Institute of Aging and Alzheimer's Disease Research, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, Texas 76107 USA ; Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, Texas 76107 USA.
Alzheimers Res Ther. 2015 May 1;7(1):24. doi: 10.1186/s13195-015-0107-4. eCollection 2015.
There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testosterone (TT) and neuropsychiatric symptoms (NPS) in a well-characterized sample of elderly men with mild to moderate AD.
The sample, which was drawn from the Texas Alzheimer's Research Care Consortium Longitudinal Research Cohort, included 87 men who met the criteria for mild to moderate AD. The occurrence of NPS was gathered from caregivers and/or family members with the Neuropsychiatric Inventory. TT was analyzed, and the sample was divided into a low-testosterone group (TT ≤2.5 ng/ml; n = 44) and a borderline/normal group (TT ≥2.6 ng/ml; n = 43).
TT was correlated with symptoms of hallucinations, delusions, agitation, irritability and motor activity. The borderline/normal group was significantly more likely to have hallucinations (odds ratio (OR) = 5.56), delusions (OR = 3.87), motor activity (OR = 3.13) and irritability (OR = 2.77) than the low-testosterone group. Health status and apolipoprotein E ε4 status were not significant factors.
The findings of the present study have implications for the use of testosterone replacement therapy in men with AD or the prodromal stage of the disease.
随着睾酮在老年男性中的应用显著增加，但对患有阿尔茨海默病（AD）的男性的影响却鲜有研究。已完成的少数研究结果不一致。在本研究中，我们研究了总睾酮（TT）与轻度至中度 AD 老年男性神经精神症状（NPS）之间的关系。
该样本取自德克萨斯州阿尔茨海默病研究护理联盟纵向研究队列，包括 87 名符合轻度至中度 AD 标准的男性。通过神经精神病学检查量表收集 NPS 的发生情况。分析 TT，将样本分为低睾酮组（TT≤2.5ng/ml；n=44）和边缘/正常组（TT≥2.6ng/ml；n=43）。
TT 与幻觉、妄想、激越、易怒和运动活动的症状相关。边缘/正常组发生幻觉（优势比（OR）=5.56）、妄想（OR=3.87）、运动活动（OR=3.13）和易怒（OR=2.77）的可能性明显高于低睾酮组。健康状况和载脂蛋白 E ε4 状态不是重要因素。
本研究的结果对 AD 或疾病前驱期男性使用睾酮替代疗法具有重要意义。
